Hikma, a London-based provider of generic injectables, has completed its acquisition of certain R&D, manufacturing and product assets from Xellia Pharmaceuticals, a Copenhagen, Denmark-headquartered specialty pharmaceutical company of anti-infectives, in a deal worth up to $185 million ($135 million upfront and $50 million in milestone payments).  

The transaction includes  Xellia’s Cleveland, Ohio manufacturing site, its in-market institutional, commercial portfolio based in Chicago, Illinois, its drug-product R&D pipeline, and the majority of the company’s R&D activities in Zagreb, Croatia.   

Xellia’s sale of these assets followed a strategic decision by the company to focus on the manufacturing and commercialization of fermentation-based anti-infective active pharmaceutical ingredients and a selected range of finished dose forms. 

 Hikma paid cash consideration of $135 million (subject to customary adjustments), with additional contingent consideration of up to $50 million payable upon achievement of certain regulatory and commercial milestones. 

Source: Hikma & Xellia Pharmaceuticals